v3.26.1
Revenue from contracts with customers and trade receivables (Details Textual)
₨ in Millions, $ in Millions
12 Months Ended
Mar. 31, 2026
INR (₨)
Mar. 31, 2026
USD ($)
Mar. 31, 2025
INR (₨)
Mar. 31, 2025
USD ($)
Mar. 31, 2024
INR (₨)
Mar. 31, 2026
USD ($)
Mar. 31, 2025
USD ($)
Statements [Line Items]              
Contract assets ₨ 64   ₨ 51        
Amount Receivable On Fda Approval     1,266 $ 15      
Revenue from sale of goods [1] 326,213   ₨ 316,320   ₨ 271,396    
Global Generics- North America Operations [Member]              
Statements [Line Items]              
Refunds provision | $           $ 47 $ 42
Global Generics Segment [Member]              
Statements [Line Items]              
Revenue from sale of goods ₨ 4,530 $ 50          
[1] For the year ended March 31, 2026, consequent to resolution of a shelf stock adjustment claim arising from a reduction in the price of its generic product Lenalidomide in the United States, the Company recorded an amount of Rs. 4,530 (U.S.$ 50) as a reduction of “Revenue from sale of goods” in the Company's Global Generics Segment.